Arjan Diepstra
dr.
As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.
Latest publications
(215)
Activities
(38)
Press/Media
(6)
Prizes
(4)
Datasets
(1)
Supervised work
(11)
Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0087474
document
The interaction between the tumor cells in classical Hodgkin lymphoma (cHL) and the microenvironment includes aberrant activity of receptor tyrosine kinases. In this study we evaluated the expression, functionality and prognostic significance of Insulin-like growth factor-1 receptor (IGF-1R) in cHL. IGF-1R was overexpressed in 55% (44/80) of cHL patients. Phosphorylated IGF-1R was detectable in a minority of the IGF-1R positive tumor cells. The overall survival (OS, 98%) and 5-year progression-free survival (PFS, 93%) was significantly higher in IGF-1R positive cHL patients compared to IGF-1R negative patients (OS 83%,...
Zheng Liang, Arjan Diepstra, Chuanhui Xu, Gustaaf van Imhoff, Wouter Plattel, Anke Van Den Berg, Lydia Visser
Long Non-Coding RNAs Are Commonly Deregulated In Hodgkin Lymphoma
Masoumeh Tayari, Klaas Kok, Gertrud Kortman, Jantine Sietzema, Debora de Jang, Martijn Terpstra, Lydia Visser, Arjan Diepstra, Joost Kluiver, Anke Van den Berg
A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc
Wendy Cozen, Dalin Li, Maria Timofeeva, Arjan Diepstra, Dennis Hazelett, Manon Delahaye-Sourdeix, Christopher K. Edlund, Klaus Rostgaard, David J. Van Den Berg, Lude Franke, Karin Eckstrom Smedby, Sally L. Glaser, Harm-Jam Westra, Leslie L. Robison, Thomas M. Mack, Herve Ghesquieres, Arnie E. Hwang, Alexandra Nieters, Silvia de Sanjose, Victoria K. CortessisTracy Lightfoot, Nikolaus Becker, Marc Maynadie, Lenka Foretova, Eve Roman, Yolanda Benavente, Bharat N. Nathwani, Bengt Glimelius, Anthony Staines, Paolo Boffetta, Brian K. Link, L. A. Kiemeney, Stephen M. Ansell, Smita Bhatia, Louise C. Strong, Pilar Galan, Lars Vatten, Thomas M. Habermann, Eric J. Duell, Annette Lake, Rianne Veenstra, Lydia Visser, Kevin Urayama, Dorothy Montgomery, Valerie Gaborieau, Lawrence Weiss, Graham Byrnes, Mark Lathrop, Hans-Olov Adami, Mads Melbye, James R. Cerhan, Alice Gallagher, G. Malcolm Taylor, Susan L. Slager, Paul Brennan, David V. Conti, Gerhard Coetzee, Kenan Onel, Ruth F. Jarrett, Henrik Hjalgrim, Anke Van Den Berg, James D. McKay
The Role of MicroRNAs in Hodgkin’s Lymphoma
Published in: MicroRNAs in Medicine
Access to document
10.1002/9781118300312.ch26
In this chapter, we summarize the current knowledge on microRNA (miRNA) expression, function and putative clinical value in Hodgkin’s lymphoma (HL). HL is the second most common lymphoma subtype, and mainly affects young adults or elderly. Malignant cells in HL are scarce, usually less than 1%, and these cells are of B-cell origin. As miRNAs are involved in almost all known biological processes, deregulation of miRNAs is thought to play an important role in the pathogenesis of HL. MiRNA expression studies have been performed on HL cell lines,...
ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Astrid Klooster, Marc A. J. Seelen, Arjan Diepstra, Jan-Stephan F. Sanders